Cantargia

Cantargia is a Swedish biotechnology company focused on developing drugs for the treatment of various cancers and inflammatory/autoimmune diseases. Our development pipeline includes the candidate product nadunolimab (CAN04), which is in Phase IIa clinical trials, CAN10, which is in the preclinical stage, and our development project CANxx.